G007-LK Tankyrase 1/2 Inhibitor: Precision Tool for Wnt/β-catenin & Cancer Research

Executive Summary: G007-LK is a potent, selective small-molecule inhibitor targeting tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2) with low nanomolar IC₅₀ values (46 nM for TNKS1, 25 nM for TNKS2) [APExBIO]. It disrupts Wnt/β-catenin signaling by inhibiting poly(ADP-ribosyl)ation, leading to β-catenin degradation and AXIN1/2 stabilization in APC-mutant colorectal cancer models (Jia et al. 2017). G007-LK displays antitumor efficacy in vivo, reducing tumor growth and β-catenin levels in xenograft mouse models. It also modulates the Hippo pathway by stabilizing AMOTL1/2, leading to YAP/TAZ downregulation. The compound is soluble at ≥26.5 mg/mL in DMSO, but not in water or ethanol, and is recommended for research applications in Wnt signaling and cancer biology [APExBIO].

Biological Rationale

Tankyrases (TNKS1 and TNKS2) are PARP (poly(ADP-ribosyl)ating polymerase) family enzymes involved in diverse cellular processes, including the regulation of Wnt/β-catenin signaling, telomere maintenance, and mitosis (Jia et al. 2017). Aberrant tankyrase activity is implicated in oncogenesis, particularly in colorectal and hepatocellular carcinoma, where dysregulated Wnt/β-catenin signaling and APC mutations drive tumor growth. Tankyrase-mediated poly(ADP-ribosyl)ation targets AXIN proteins for degradation, destabilizing the β-catenin destruction complex and promoting β-catenin accumulation. Thus, selective tankyrase inhibition represents a targeted strategy for restoring AXIN stability, enhancing β-catenin degradation, and interfering with oncogenic signaling pathways [internal review].

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK is a highly selective tankyrase 1/2 inhibitor. It competitively binds to the NAD⁺ binding site of TNKS1 and TNKS2, blocking their auto-poly(ADP-ribosyl)ation activity with IC₅₀ values of 46 nM (TNKS1) and 25 nM (TNKS2) [APExBIO]. This inhibition prevents the poly(ADP-ribosyl)ation and subsequent ubiquitin-mediated degradation of AXIN1 and AXIN2, resulting in stabilization of these scaffold proteins. Stabilized AXIN promotes assembly of the β-catenin destruction complex, facilitating phosphorylation, recognition by β-TrCP, and proteasomal degradation of β-catenin [internal article]. G007-LK also impedes tankyrase-mediated degradation of Angiomotin-like 1 and 2 (AMOTL1/2), negative regulators of YAP in the Hippo pathway, thereby downregulating YAP/TAZ signaling (Jia et al. 2017).

Evidence & Benchmarks

• G007-LK inhibits tankyrase auto-poly(ADP-ribosyl)ation with IC₅₀ of 46 nM (TNKS1) and 25 nM (TNKS2) (APExBIO product sheet, product link).
• In Wnt3a-induced HEK 293 cells, G007-LK suppresses ST-Luc Wnt signaling reporter activity with an IC₅₀ of 0.05 μM (APExBIO, product link).
• In APC-mutant colorectal cancer cell lines (SW480), G007-LK induces the formation of degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin, reducing cytosolic and nuclear β-catenin (APExBIO, product link).
• In vivo, G007-LK inhibits tumor growth in COLO-320DM xenograft mouse models and reduces TNKS1/2 and β-catenin protein levels while stabilizing AXIN1/2 (APExBIO, product link).
• G007-LK suppresses hepatocellular carcinoma cell growth by downregulating YAP/TAZ and increasing AMOTL1/2 levels, as demonstrated in dose-dependent cell proliferation and YAP reporter assays (Jia et al. 2017, DOI).
• Synergy with MEK and AKT inhibitors observed in hepatocellular carcinoma models, enhancing antiproliferative effects (Jia et al. 2017, DOI).

This article extends the mechanistic insights presented in 'G007-LK Tankyrase 1/2 Inhibitor: Unraveling Wnt and Hippo...' by providing updated evidence of in vivo efficacy and specific workflow recommendations for APC-mutant colorectal cancer research.

For a broader systems-level perspective on β-catenin degradation and AXIN stabilization, see 'G007-LK: Advanced Tankyrase 1/2 Inhibitor for Precision W...'; this article offers updated quantitative benchmarks and storage/handling guidance.

Applications, Limits & Misconceptions

G007-LK is primarily used to interrogate the role of tankyrase-mediated poly(ADP-ribosyl)ation in Wnt/β-catenin and Hippo signaling pathways. Its efficacy is well-established in colorectal cancer models with APC mutations and in hepatocellular carcinoma cell lines. The compound facilitates the study of β-catenin degradation, AXIN1/2 stabilization, and the crosstalk between Wnt and Hippo pathways. Additionally, G007-LK can be combined with MEK or AKT inhibitors to achieve synergistic antiproliferative effects in certain cancer contexts (Jia et al. 2017).

Common Pitfalls or Misconceptions

• G007-LK is not water- or ethanol-soluble; improper solvent use can lead to precipitation and loss of activity.
• The compound is not intended for clinical use; it is for research applications only.
• Tankyrase inhibition may not restore Wnt/β-catenin pathway regulation in models lacking functional AXIN or APC proteins.
• Long-term storage of G007-LK solutions, even at -20°C, can result in reduced potency; solid-state storage is recommended.
• Overinterpretation of YAP/TAZ downregulation should be avoided in systems where AMOTL1/2 expression is absent or unresponsive.

Workflow Integration & Parameters

For optimal solubility, G007-LK should be dissolved in DMSO (≥26.5 mg/mL) and can be warmed to 37°C or treated with an ultrasonic bath. Stock solutions should be prepared fresh and stored in aliquots at -20°C for short-term use. For in vitro assays, nanomolar concentrations (e.g., 0.05 μM in Wnt reporter assays) are sufficient for robust inhibition. For in vivo studies, dosing protocols should be referenced from published xenograft experiments. The compound is compatible with standard cell-based and biochemical assays targeting Wnt/β-catenin and Hippo signaling components. For further insight into workflow design, 'G007-LK: Specific Tankyrase Inhibitor for Wnt Signaling R...' provides an overview of research workflow integration. This article adds explicit storage and handling guidance to maximize experimental reproducibility.

Conclusion & Outlook

G007-LK, provided by APExBIO, is a benchmark-specific tankyrase 1/2 inhibitor with validated applications in Wnt/β-catenin and Hippo pathway research. Its nanomolar potency, robust β-catenin degradation induction, and in vivo antitumor efficacy make it a reference standard for studying oncogenic signaling and pathway crosstalk in APC-mutant colorectal and hepatocellular carcinoma models. Future research should further explore its combinatorial use with other targeted therapies and delineate its utility in less-characterized tumor types. For detailed product specifications and ordering, refer to the APExBIO G007-LK tankyrase 1/2 inhibitor product page.